No abstract available
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Amides / adverse effects
-
Amides / therapeutic use
-
Animals
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / metabolism
-
Atherosclerosis / physiopathology*
-
Cannabinoid Receptor Modulators / physiology*
-
Disease Models, Animal
-
Endocannabinoids*
-
Humans
-
Macrophages / metabolism
-
Mice
-
Piperidines / adverse effects
-
Piperidines / therapeutic use
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Pyridines / adverse effects
-
Pyridines / therapeutic use
-
Reactive Oxygen Species / metabolism
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB1 / physiology
-
Receptor, Cannabinoid, CB2 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB2 / physiology
-
Rimonabant
-
Signal Transduction / physiology*
Substances
-
Amides
-
Cannabinoid Receptor Modulators
-
Endocannabinoids
-
Piperidines
-
Pyrazoles
-
Pyridines
-
Reactive Oxygen Species
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Rimonabant
-
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide